1. Home
  2. OCEA vs COHN Comparison

OCEA vs COHN Comparison

Compare OCEA & COHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCEA
  • COHN
  • Stock Information
  • Founded
  • OCEA 2019
  • COHN 1999
  • Country
  • OCEA United States
  • COHN United States
  • Employees
  • OCEA N/A
  • COHN N/A
  • Industry
  • OCEA Biotechnology: Pharmaceutical Preparations
  • COHN Investment Bankers/Brokers/Service
  • Sector
  • OCEA Health Care
  • COHN Finance
  • Exchange
  • OCEA Nasdaq
  • COHN Nasdaq
  • Market Cap
  • OCEA 20.5M
  • COHN 18.5M
  • IPO Year
  • OCEA N/A
  • COHN N/A
  • Fundamental
  • Price
  • OCEA $0.13
  • COHN $9.50
  • Analyst Decision
  • OCEA
  • COHN
  • Analyst Count
  • OCEA 0
  • COHN 0
  • Target Price
  • OCEA N/A
  • COHN N/A
  • AVG Volume (30 Days)
  • OCEA 88.9M
  • COHN 4.6K
  • Earning Date
  • OCEA 01-13-2025
  • COHN 03-05-2025
  • Dividend Yield
  • OCEA N/A
  • COHN 10.53%
  • EPS Growth
  • OCEA N/A
  • COHN N/A
  • EPS
  • OCEA N/A
  • COHN 2.35
  • Revenue
  • OCEA N/A
  • COHN $89,555,000.00
  • Revenue This Year
  • OCEA N/A
  • COHN N/A
  • Revenue Next Year
  • OCEA N/A
  • COHN N/A
  • P/E Ratio
  • OCEA N/A
  • COHN $4.05
  • Revenue Growth
  • OCEA N/A
  • COHN 63.18
  • 52 Week Low
  • OCEA $0.11
  • COHN $6.10
  • 52 Week High
  • OCEA $7.79
  • COHN $12.82
  • Technical
  • Relative Strength Index (RSI)
  • OCEA 28.02
  • COHN 43.32
  • Support Level
  • OCEA $0.12
  • COHN $9.43
  • Resistance Level
  • OCEA $0.16
  • COHN $9.79
  • Average True Range (ATR)
  • OCEA 0.04
  • COHN 0.30
  • MACD
  • OCEA 0.01
  • COHN 0.02
  • Stochastic Oscillator
  • OCEA 8.66
  • COHN 37.50

About OCEA Ocean Biomedical Inc.

Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

Share on Social Networks: